AnaptysBio, Inc. (ANAB)
$46.04+0.20%Close
SELLCRISIS · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.0B
- Beta
- 0.41
- P/E (TTM)
- 7.09
- Short % float
- 13.00%
- Days to cover
- 8.2
- SI change
- -3.7%
- 1W
- -6.42%
- 1M
- -14.53%
- vs SPY 1W
- -6.84%
- vs SPY 1M
- -16.60%
Industry peers
FMP comparable companies · ranked by market cap
- IMVTSELLImmunovant, Inc.$6.3BCRISISQ 25$30.47-3.25%
- DNTHSELLDianthus Therapeutics, Inc.$4.6BCRISISQ 2$82.37-0.97%
- XNCRSELLXencor, Inc.$1.8BRECOVERYQ 16$24.63+1.66%
- ODTXSELLOdyssey Therapeutics, Inc.$913MQ 31$19.00-3.89%
- MLTXSELLMoonLake Immunotherapeutics$910MCRISISQ -0$10.82-1.29%
- ANNXSELLAnnexon, Inc.$659MRECOVERYQ -9$4.02-1.49%
- ACRSSELLAclaris Therapeutics, Inc.$535MCRISISQ 9$3.83-6.01%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on ANAB?
- LOPJLB’s latest quantitative signal on AnaptysBio, Inc. (ANAB) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ANAB in?
- AnaptysBio, Inc. (ANAB) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does AnaptysBio, Inc. (ANAB) do?
- AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The companyâs products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b t…